Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 over exp |
| Therapy | Retifanlimab |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 over exp | lung non-small cell carcinoma | predicted - sensitive | Retifanlimab | Phase II | Actionable | In a Phase II trial (POD1UM-203), Zynyz (retifanlimab) treatment was well tolerated and demonstrated antitumor activity in non-small cell lung cancer patients with high CD274 (PD-L1) expression (TPS >/= 50%), resulting in an overall response rate of 34.8% (8/23, 8 partial responses), disease control rate of 65.2%, median progression-free survival of 4.4 months, and median duration of response and median overall survival were not reached (PMID: 38401247; NCT03679767). | 38401247 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38401247) | A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203). | Full reference... |